People · Operator
Named in public records as an officer, director or promoter · active 2019–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Grail, Inc. | — | Biotechnology | Growth/Late | $2.2B | $2.9B | 2019 |
| Neumora Therapeutics, Inc. | — | Biotechnology | Growth/Late | $474.4M | $19.0B | 2020 |
MAYKIN HO at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside MAYKIN HO on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 2 | 22 |
| Kristina Burow | 1 | 16 |
| Richard Klausner | 1 | 7 |
| Robert T. Nelsen | 1 | 5 |
| MIN CUI | 1 | 5 |
| Matthew Fust | 1 | 4 |
| William Rastetter | 1 | 4 |
| Stacie Weninger | 1 | 4 |
| Hans Bishop | 1 | 3 |
| Catherine Friedman | 1 | 3 |
| Paul Berns | 1 | 3 |
| JEFFREY HUBER | 1 | 2 |
| Tamara Tompkins | 1 | 2 |
| William T. Rastetter | 1 | 2 |
| Jeffrey T. Huber | 1 | 2 |
| Alaa Halawa | 1 | 2 |
| Robert Ragusa | 1 | 1 |
| Josh Ofman | 1 | 1 |
| Gregory Summe | 1 | 1 |
| HAL BARRON | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.